≡

Multiplex Assay Kit for Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) ,etc. by FLIA (Flow Luminescence Immunoassay)

NB; DAN; NO3; DAND1; Differential Screening-Selected Gene Aberrant In Neuroblastoma; DAN domain family member 1

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 95-104 101
EDTA plasma(n=5) 86-101 92
heparin plasma(n=5) 94-102 98
sodium citrate plasma(n=5) 89-103 94

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 79-94% 79-99% 80-97% 78-92%
EDTA plasma(n=5) 98-105% 80-90% 95-102% 91-99%
heparin plasma(n=5) 86-96% 98-105% 97-105% 82-96%
sodium citrate plasma(n=5) 83-92% 78-104% 82-105% 88-96%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:NBL1) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPP853Hu01 Recombinant Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) Positive Control; Immunogen; SDS-PAGE; WB.
PAP853Hu01 Polyclonal Antibody to Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) WB; IHC; ICC; IP.
MAP853Hu21 Monoclonal Antibody to Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) WB; IHC; ICC; IP.
SEP853Hu ELISA Kit for Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) Enzyme-linked immunosorbent assay for Antigen Detection.
SCP853Hu CLIA Kit for Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) Chemiluminescent immunoassay for Antigen Detection.
LMP853Hu Multiplex Assay Kit for Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.
CGP853Hu01 cDNA of Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) PCR; Protein Expression; etc.